NasdaqGM - Nasdaq Real Time Price USD

Rani Therapeutics Holdings, Inc. (RANI)

0.5599

+0.0054

+(0.97%)

At close: June 4 at 4:00:01 PM EDT

Rani Therapeutics Announces Research Agreement with Chugai

- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets

GlobeNewswire 16 days ago

RANI
+0.97%
RANI: 1Q:25 Financial Results

By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT On May 13 th Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported first quarter 2025 results. Year to date, Rani has updated investors on ProGen’s PG102 asset and reported preclinical data for RT-114 and RT-116, or RaniPill semaglutide. In the financial sphere, the company paid down $3.8 million of debt and consumed

Zacks Small Cap Research 16 days ago

RANI
+0.97%
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase 1 study for RT-114 for the treatment of obesity expected to initiate in mid-2025 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani

GlobeNewswire 22 days ago

RANI
+0.97%
RANI: 2024 Financial Results

By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT On March 31 st , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported 2024 results. Since the third quarter report, Rani has participated in multiple investor conferences, raised an additional $10 million and reported glucagon-like peptide-1 receptor (GLP-1) incretin triagonist data. Most importantly, Rani’s lead program,

Zacks Small Cap Research 2 months ago

RANI
+0.97%
Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Despite a significant decrease in cash reserves, Rani Therapeutics Holdings Inc (RANI) focuses on advancing its promising RaniPill technology and strategic programs.

GuruFocus.com 2 months ago

RANI
+0.97%
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-

GlobeNewswire 2 months ago

RANI
+0.97%
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 – - Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in obese patients, with an average reduction of 4.8% and up to 8.7% following five weeks of dosing - - Data bols

GlobeNewswire 2 months ago

RANI
+0.97%
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani’s management team will host a conference call and webcast begin

GlobeNewswire 2 months ago

RANI
+0.97%
RANI: Impressive Bioavailability for RT-116

By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of semaglutide using the RaniPill High Capacity (HC) device compared to subcutaneous (SC) injection. The study was conducted in eight canines to generate

Zacks Small Cap Research 3 months ago

RANI
+0.97%
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week

Key Insights The considerable ownership by individual investors in Rani Therapeutics Holdings indicates that they...

Simply Wall St. 3 months ago

RANI
+0.97%
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated with no serious adverse events - - Data adds to growing body of evidence of the RaniPill® platform’s potential to enable oral delivery of multiple obesity treatments - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Cal

GlobeNewswire 3 months ago

RANI
+0.97%
RANI: Third Quarter Update

By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported third quarter 2024 results on November 14 th , 2024. Since the second quarter report, Rani has participated in multiple investor conferences, raised an additional $10 million and reported data for a GLP-1 incretin triagonist, which we review below. We are looking ahead

Zacks Small Cap Research 6 months ago

RANI
+0.97%
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a cli

GlobeNewswire 6 months ago

RANI
+0.97%
Rani Therapeutics to Participate in Upcoming Investor Conferences

SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in three upcoming conferences. These conferences include: UBS Global Healthcare Conference Location: Terranea Resort, Rancho Palos Verdes, CADate: Thursday, November 14, 2024 at 10:15am PTFormat: Fireside

GlobeNewswire 6 months ago

RANI
+0.97%
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch

As the U.S. markets face a downturn with major indexes like the Dow Jones and Nasdaq experiencing significant losses, investors are reevaluating their strategies amid rising Treasury yields and fluctuating earnings reports. In such volatile times, identifying stocks with solid financial foundations becomes crucial for those looking to navigate uncertain waters. Penny stocks, though an older term, continue to represent smaller or emerging companies that can offer unique opportunities when...

Simply Wall St. 7 months ago

RANI
+0.97%

XNET

AGAE
RANI: New Triagonist Data in Weight Loss

By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) provided a look at new preclinical data for a glucagon-like peptide-1 (GLP-1) incretin triagonist. In addition to a discussion to this data, we review the recent $10 million capital raise. The molecule reviewed in the October 17th press release demonstrated 80% bioavailability

Zacks Small Cap Research 7 months ago

RANI
+0.97%
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection - - New pharmacokinetic data provides further evidence of the RaniPill platform’s potential to enable oral delivery of multiple obesity treatments - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Oct.

GlobeNewswire 7 months ago

RANI
+0.97%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 7 months ago

RANI
+0.97%

SEEL
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics’ Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 333,333 shares of

GlobeNewswire 7 months ago

RANI
+0.97%
Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks

Investors have plenty to feel positive about. Inflation is easing, with the latest data showing an annualized rate of 2.4%, just shy of the Fed’s target by less than half a percentage point. Meanwhile, the stock market continues its bullish run, with the S&P 500 hitting a record high of 5,822 on Friday, marking a 22% year-to-date gain. The naysayers have, so far, been proven wrong – the economy, at least as far as the stock market is concerned, remains robust. Oppenheimer’s chief investment stra

TipRanks 7 months ago

RANI
+0.97%

UCTT

Performance Overview

Return	RANI	S&P 500 (^GSPC)
YTD	-59.13%	+1.52%
1-Year	-88.01%	+12.84%
3-Year	-94.67%	+45.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics Announces Research Agreement with Chugai

RANI: 1Q:25 Financial Results

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

RANI: 2024 Financial Results

Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

RANI: Impressive Bioavailability for RT-116

Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

RANI: Third Quarter Update

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics to Participate in Upcoming Investor Conferences

Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch

RANI: New Triagonist Data in Weight Loss

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

Top Midday Decliners

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks

Performance Overview